[ad_1]
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), as we speak introduced that the Firm’s second quarter 2022 monetary outcomes shall be launched after market shut on Tuesday, August 9, 2022. ChemoCentryx govt administration will host a convention name and webcast starting at 5:00 p.m. Jap Time on August 9, 2022 to debate these outcomes and to reply questions.
To take part by phone, please dial (800) 715-9871 (Home) or (646) 307-1963 (Worldwide). The convention ID quantity is 9726781. A reside and archived audio webcast may be accessed by means of the Traders part of the Firm’s web site at www.ChemoCentryx.com. The archived webcast will stay out there on the Firm’s web site for fourteen (14) days following the decision.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical firm commercializing and growing new drugs for inflammatory and autoimmune ailments and most cancers. ChemoCentryx targets the chemokine and chemoattractant methods to find, develop and commercialize orally administered therapies.
In the United States, ChemoCentryx markets TAVNEOS® (avacopan), the primary accepted orally administered inhibitor of the complement 5a receptor as an adjunctive remedy for grownup sufferers with extreme lively ANCA-associated vasculitis. TAVNEOS can also be in late-stage scientific improvement for the remedy of extreme hidradenitis suppurativa (HS) and C3 glomerulopathy (C3G).
ChemoCentryx can also be growing CCX559, a extremely potent orally administered small molecule PD-L1 checkpoint inhibitor, for the remedy of sufferers with stable tumors. A Section I dose escalation examine for CCX559 is ongoing and ChemoCentryx plans to advance to a Section Ib/II examine within the second half of 2022.
Moreover, ChemoCentryx has early-stage drug candidates that focus on chemoattractant receptors in different inflammatory and autoimmune ailments and in most cancers. For extra details about the Firm go to www.ChemoCentryx.com.
TAVNEOS® is a registered trademark of ChemoCentryx, Inc. For extra data, please see the Full Prescribing Info and Treatment Information, out there at TAVNEOS.com.
ChemoCentryx Contacts
Traders:
Invoice Slattery, Jr.
Vice President, Investor Relations
& Company Communications
650.210.2970
bslattery@chemocentryx.com
Media:
Alex Straus
Investor Relations & Company
Communications Supervisor
astraus@chemocentryx.com
[ad_2]
Supply hyperlink